(Q53616304)

16 May 2018

title

An evaluation of the efficacy of topical application of salicylic acid for the treatment of familial cylindromatosis. (English)

1 reference

16 May 2018

Medical uses of salicylic acid

main subject

1 reference

1 reference

6

1 reference

16 May 2018

author name string

Oosterkamp HM

1

1 reference

16 May 2018

Neering H

2

1 reference

16 May 2018

Nijman SM

3

1 reference

16 May 2018

Dirac AM

4

1 reference

16 May 2018

Mooi WJ

5

1 reference

16 May 2018

Brummelkamp TR

7

1 reference

16 May 2018

language of work or name

English

0 references

publication date

1 July 2006

1 reference

16 May 2018

British Journal of Dermatology

published in

1 reference

16 May 2018

volume

155

1 reference

16 May 2018

issue

1

1 reference

16 May 2018

page(s)

182-185

1 reference

16 May 2018

Familial cutaneous cylindromas: investigations in five generations of a family

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07224.X

Identification of the familial cylindromatosis tumour-suppressor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07224.X

Familial cylindromatosis (turban tumour syndrome) gene localised to chromosome 16q12-q13: evidence for its role as a tumour suppressor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07224.X

Chemistry-based functional proteomics reveals novel members of the deubiquitinating enzyme family

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07224.X

CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07224.X

Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07224.X

The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07224.X

NF-kappaB in cancer: from innocent bystander to major culprit

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07224.X

The NF-kappaB signalling pathway in human diseases: from incontinentia pigmenti to ectodermal dysplasias and immune-deficiency syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07224.X

The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07224.X

Putting the brakes on cylindromatosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07224.X

Signal transduction: aspirin, ubiquitin and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07224.X

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07224.X

BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07224.X

Targeting NF-kappaB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07224.X

10.1111/J.1365-2133.2006.07224.X

21 January 2018

Identifiers

DOI

1 reference

16 May 2018

1 reference

16 May 2018